Showing results 1 to 20 of 285

Costly to protect, attack pharma IP in India

Supreme Court judgment rejecting Novartis' plea for a patent on cancer drug, Glivec, highlights the need for developing new models of selling innovative drugs in markets like India where patients can't afford costly, life-saving drugs.

April 3, 2013 by

The best of ZDNet, delivered

You have been successfully signed up. To sign up for more newsletters or to manage your account, visit the Newsletter Subscription Center.
Subscription failed.

Top Stories